Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients
NCT04259372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77
Last updated 2020-02-06
Summary
The objective of this study was to analyze the T cell metabolism and immune phenotype in AML patients during the course of the disease before and after allo-HCT.
Conditions
Sponsors & Collaborators
-
University of Freiburg
lead OTHER
Principal Investigators
-
Robert Zeiser, Prof. Dr. · Medical Center University of Freiburg
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-01-01
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
More Related Trials
-
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
NCT06279572 ·Status: RECRUITING
-
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)
NCT00808080 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
NCT02927938 ·Status: TERMINATED ·Phase: PHASE3
-
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
NCT02581917 ·Status: COMPLETED
-
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
NCT00337519 ·Status: UNKNOWN ·Phase: PHASE2
-
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
NCT00897182 ·Status: COMPLETED
-
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916 ·Status: RECRUITING
-
Chronic Myelod Leukemia Registry at Asan Medical Center
NCT01761695 ·Status: TERMINATED
-
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
NCT00880243 ·Status: COMPLETED ·Phase: PHASE3
-
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
NCT03597321 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
NCT02770820 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
CD155 Expression in Acute Myeloid Leukemia
NCT06369662 ·Status: COMPLETED
-
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
NCT03964922 ·Status: UNKNOWN ·Phase: NA
-
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
NCT03488862 ·Status: COMPLETED
-
Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment
NCT04321161 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
NCT00458523 ·Status: COMPLETED ·Phase: PHASE2
-
flt3L in Treating Patients With Acute Myeloid Leukemia
NCT00006223 ·Status: COMPLETED ·Phase: PHASE3
-
Microtransplantation in Older Patients With Acute Myeloid Leukemia
NCT02831192 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150 ·Status: COMPLETED
-
Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"
NCT05304156 ·Status: RECRUITING
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562 ·Status: RECRUITING ·Phase: PHASE3
-
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML
NCT02888522 ·Status: UNKNOWN
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
NCT03080922 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes
NCT00038870 ·Status: WITHDRAWN ·Phase: NA